Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique

• Published in: BMJ open Vol. 11; no. 9; p. e050671
• Main Authors: Mussá, Merana, Gaspar, Irénio, Namburete, Luisa, Sitoie, Tânia Vuyeya, Couto, Aleny, Paulino, Jamal Mario, Lemos, Abrao, Vilanculos, Stefia, Ogar, Comfort Kunak, Namburete, Denylson, Seni, Eunice Dias, Hafner, Tamara, Stergachis, Andy
• Format: Journal Article
• Language: English
• Published: London British Medical Journal Publishing Group 07.09.2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiretroviral drugs; Birth defects; Collaboration; Data collection; Drug resistance; health & safety; HIV; HIV & AIDS; Human immunodeficiency virus; Infections; Insomnia; Maternal & child health; Patients; Pharmacy; Pregnancy; protocols & guidelines; public health; Schedules; Surveillance
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-050671

IntroductionDolutegravir-based antiretroviral therapy (ART) is increasingly being used as the preferred first-line regimen for the treatment of HIV in low-income and middle-income countries. The National Program for the Control of STI/HIV/AIDS in Mozambique has planned a phased introduction of the tenofovir/lamivudine/dolutegravir (TLD) regimen. In 2019, concerns about a potential safety signal identified with dolutegravir identified in the results of the Tsepamo study, conducted in Botswana, led the National Directorate of Pharmacy and the National Program for the Control of STI/HIV/AIDS to establish an active pharmacovigilance surveillance system among newly placed patients on a TLD regimen. This activity aims to establish an active pharmacovigilance system to monitor adverse events in patients on a TLD regimen to support the effectiveness of Mozambique’s public health programmes in improving the process of care and treatment outcomes for people with HIV/AIDS.Methods and analysisThis is a prospective, non-interventional, descriptive cohort study to monitor HIV patients managed with TLD at 10 sentinel health centres in Mozambique. The cohort consists of HIV-infected patients commencing treatment with TLD, either as treatment naïve patients or switched from other ART regimens. Patients have monthly routine follow-up visits for the first 3 months after starting HIV treatment with TLD, and subsequently every 3 months for a total period of 1 year. Patients are monitored to identify possible adverse events during the follow-up period. The intended size of the cohort is 3000 patients.Ethics and disseminationEthical approval was obtained from the National Commission on Bioethics in Health in Mozambique. Written informed consent is obtained from each participant who agrees to participate to have their information collected, analysed and stored. Findings will be reported to the Ministry of Health and participating health centres to inform policy and practice as well as disseminated by peer-review publications.